Mr. John Price reports

TELO GENOMICS GRANTS STOCK OPTIONS

Telo Genomics Corp. has granted stock options pursuant to its stock option plan to purchase up to an aggregate of 3.3 million common shares of the company, subject to TSX Venture Exchange approval, of which 2.5 million options were granted to directors and officers, 600,000 options to employees, and 200,000 options to consultants of the company. The options are exercisable at a price of 5.5 cents per share and expire five years from the date of grant. The options vest immediately upon grant.

The option grants were made to reward the current Telo team for their past and ongoing efforts and to incentivize contributions to Telo's success moving forward.

The options granted to directors, officers and consultants of the company, and the underlying shares, are subject to a four-month hold period in accordance with the policies of the TSX Venture Exchange.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the company's team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of the company's proprietary technology have been substantiated in 160-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. The company's lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.